CELL INTELLIGENCE · 肿瘤细胞治疗研究

首个获批用于实体瘤的 CAR-T 细胞疗法

First CAR T-Cell Therapy Approved for Solid Tumors.

可编程工程菌调控代谢并原位重塑 TME 以增强过继性细胞治疗

Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.

CAR 为基础的细胞治疗在胃肠道恶性肿瘤中的临床试验概况

Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies.

Claudin18.2 特异性 IL-7/XCL1 装甲 CAR-T 细胞在消化道肿瘤中的疗效与免疫调节作用：临床前与临床分析

Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysi

claudin 18.2 靶向免疫疗法的靶向/非肿瘤毒性建模与应对

Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies.

实体瘤 CAR-T 细胞治疗的挑战与最新进展

Challenges and recent advances in CAR-T cell therapy for solid tumors.

基于机制数据的多尺度定量系统药理学建模框架助力实体瘤 CAR-T 治疗的临床转化与疗效评估

Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of

我们的转化型 QSP 平台提供了一条创新路径，用于整合多尺度知识并为新型靶向实体瘤的 CAR-T 疗法的临床决策提供依据。

CLDN18.2 阳性肿瘤的耐药机制与应对策略：从分子网络到临床实践

Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice.

实体瘤的 CAR-T 细胞治疗：复杂机制与潜在策略综述

Chimeric antigen receptor T-cell therapy for solid tumors: A review of the intricate mechanisms and potential strategies.